Erdheim-Chester disease associated with a novel, complex BRAF p.Thr599_Val600delinsArgGlu mutation
MetadataShow full item record
BRAF mutation testing to determine eligibility for treatment with vemurafenib was performed on archival skin lesions of a 54-year-old patient diagnosed with Erdheim-Chester disease (ECD) in 1999. Sanger sequencing of DNA extracted from a 2008 skin lesion identified two non-contiguous base substitutions in BRAF, which were shown by next-generation sequencing (NGS) to be located in the same allele. Due to its long-standing duration, molecular evolution of disease was possible; however, both Sanger and NGS of a 2000 skin lesion were unsuccessful due to the poor quality of DNA. Finally, droplet digital PCR using a probe specific for this novel mutation detected the complex BRAF mutation in both the 2000 and 2008 lesions, indicating this case to be ECD with a novel underlying BRAF p.Thr599-Val600delinsArgGlu mutation. Although well at present, molecular modelling of the mutant BRAF suggests suboptimal binding of vemurafenib and hence reduced therapeutic effectiveness.
Showing items related by title, author, creator and subject.
Population-based detection of lynch syndrome in young colorectal cancer patients using microsatellite instability as the initial testSehofield, L.; Watson, N.; Grieu, F.; Wei, Q.; Zeps, Nikolajs; Harvey, J.; Stewart, C.; Abclo, M.; Goldblatt, J.; Iacopetta, B. (2009)Approximately 1-2% of colorectal cancers (CRC) arise because of germline mutations in UNA mismatch repair genes, referred to as Lynch syndrome. These tumours show microsatellite instability (MSI) and loss of expression ...
Stomach-specific activation of oncogenic KRAS and STAT3-dependent inflammation cooperatively promote gastric tumorigenesis in a preclinical modelThiem, S.; Eissmann, M.; Elzer, J.; Jonas, A.; Putoczki, T.; Poh, A.; Nguyen, P.; Preaudet, A.; Flanagan, D.; Vincan, Elizabeth; Waring, P.; Buchert, M.; Jarnicki, A.; Ernst, M. (2016)About 5% to 10% of human gastric tumors harbor oncogenic mutations in the KRAS pathway, but their presence alone is often insufficient for inducing gastric tumorigenesis, suggesting a requirement for additional mutagenic ...
Saei, A.; Eichhorn, Pieter (2019)© 2019 by the authors. The introduction of v-raf murine sarcoma viral oncogene homolog B (BRAF) inhibitors in melanoma patients with BRAF (V600E) mutations has demonstrated significant clinical benefits. However, rarely ...